A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2017 Oct 18

PMID 29038269

Citations 102

Authors

Karlijn van Loon

Anne F Voor In t Holt

Margreet C Vos

Affiliations

Soon will be listed here.

Abstract

Carbapenem-resistant (CRE) are major health care-associated pathogens and responsible for hospital outbreaks worldwide. To prevent a further increase in CRE infections and to improve infection prevention strategies, it is important to summarize the current knowledge about CRE infection prevention in hospital settings. This systematic review aimed to identify risk factors for CRE acquisition among hospitalized patients. In addition, we summarized the environmental sources/reservoirs and the most successful infection prevention strategies related to CRE. A total of 3,983 potentially relevant articles were identified and screened. Finally, we included 162 studies in the systematic review, of which 69 studies regarding risk factors for CRE acquisition were included in the random-effects meta-analysis studies. The meta-analyses regarding risk factors for CRE acquisition showed that the use of medical devices generated the highest pooled estimate (odds ratio [OR] = 5.09; 95% confidence interval [CI] = 3.38 to 7.67), followed by carbapenem use (OR = 4.71; 95% CI = 3.54 to 6.26). To control hospital outbreaks, bundled interventions, including the use of barrier/contact precautions for patients colonized or infected with CRE, are needed. In addition, it is necessary to optimize the therapeutic approach, which is an important message to infectious disease specialists, who need to be actively involved in a timely manner in the treatment of patients with known CRE infections or suspected carriers of CRE.

Citing Articles

Carbapenem-resistant Enterobacterales (CRE) colonisation as a predictor for subsequent CRE infection: A retrospective surveillance study.

Tubb C, Tubb M, Hooijer J, Chomba R, Nel J S Afr J Infect Dis. 2025; 40(1):687.

PMID: 39968233 PMC: 11830835. DOI: 10.4102/sajid.v40i1.687.

Risk factors for Carbapenem-resistant Enterobacterales infections: A case-control study.

Mbele S, Vasaikar S S Afr Fam Pract (2004). 2025; 67(1):e1-e10.

PMID: 39935157 PMC: 11886460. DOI: 10.4102/safp.v67i1.6029.

A Multidisciplinary-Based and Bundle Intervention for Controlling Carbapenem-Resistant Organisms in Neurosurgery.

Zhu W, Liang Y, Xu J, Weng C Infect Drug Resist. 2025; 18:757-768.

PMID: 39931038 PMC: 11809232. DOI: 10.2147/IDR.S506658.

Carbapenem-resistant Enterobacterales infection and colonization in patients with severe burns: a retrospective cohort study in a single burn center.

Kim M, Jeon K, Kym D, Jung J, Jang Y, Han S Antimicrob Resist Infect Control. 2025; 14(1):3.

PMID: 39881424 PMC: 11780852. DOI: 10.1186/s13756-025-01514-9.

Disseminated organ and tissue infection secondary to carbapenem-resistant Klebsiella pneumoniae bloodstream infection for acute lymphoblastic leukemia treated with ceftazidime-avibactam: Two case reports.

He M, Jiang Y, Wu H, Xu X, Jiang H Medicine (Baltimore). 2025; 104(2):e41195.

PMID: 39792772 PMC: 11730841. DOI: 10.1097/MD.0000000000041195.

References

Ho H, Toh C, Ang B, Krishnan P, Lin R, La M . Outbreak of New Delhi metallo-β-lactamase-1-producing Enterobacter cloacae in an acute care hospital general ward in Singapore. Am J Infect Control. 2015; 44(2):177-82. DOI: 10.1016/j.ajic.2015.08.028. View

Liu S, Chang H, Chia J, Kuo A, Wu T, Lee M . Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. J Microbiol Immunol Infect. 2011; 45(2):113-9. DOI: 10.1016/j.jmii.2011.09.026. View

Gagliotti C, Giordani S, Ciccarese V, Barozzi A, Giovinazzi A, Pietrantonio A . Risk factors for colonization with carbapenemase-producing Klebsiella pneumoniae in hospital: a matched case-control study. Am J Infect Control. 2014; 42(9):1006-8. DOI: 10.1016/j.ajic.2014.05.028. View

. Carbapenem-resistant Klebsiella pneumoniae associated with a long-term--care facility --- West Virginia, 2009-2011. MMWR Morb Mortal Wkly Rep. 2011; 60(41):1418-20. View

Temkin E, Adler A, Lerner A, Carmeli Y . Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci. 2014; 1323:22-42. DOI: 10.1111/nyas.12537. View

Marsh J, Krauland M, Nelson J, Schlackman J, Brooks A, Pasculle A . Genomic Epidemiology of an Endoscope-Associated Outbreak of Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae. PLoS One. 2015; 10(12):e0144310. PMC: 4670079. DOI: 10.1371/journal.pone.0144310. View

Garbati M, Sakkijha H, Abushaheen A . Infections due to Carbapenem Resistant Enterobacteriaceae among Saudi Arabian Hospitalized Patients: A Matched Case-Control Study. Biomed Res Int. 2016; 2016:3961684. PMC: 4837245. DOI: 10.1155/2016/3961684. View

Cheng V, Chen J, So S, Wong S, Chau P, Wong L . A Novel Risk Factor Associated With Colonization by Carbapenemase-Producing Enterobacteriaceae: Use of Proton Pump Inhibitors in Addition to Antimicrobial Treatment. Infect Control Hosp Epidemiol. 2016; 37(12):1418-1425. DOI: 10.1017/ice.2016.202. View

Lin M, Lyles-Banks R, Lolans K, Hines D, Spear J, Petrak R . The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2013; 57(9):1246-52. PMC: 8383150. DOI: 10.1093/cid/cit500. View

10.

Borer A, Saidel-Odes L, Eskira S, Nativ R, Riesenberg K, Livshiz-Riven I . Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae. Am J Infect Control. 2011; 40(5):421-5. DOI: 10.1016/j.ajic.2011.05.022. View

11.

Douka E, Perivolioti E, Kraniotaki E, Fountoulis K, Economidou F, Tsakris A . Emergence of a pandrug-resistant VIM-1-producing Providencia stuartii clonal strain causing an outbreak in a Greek intensive care unit. Int J Antimicrob Agents. 2015; 45(5):533-6. DOI: 10.1016/j.ijantimicag.2014.12.030. View

12.

Chen S, Hu F, Liu Y, Zhu D, Wang H, Zhang Y . Detection and spread of carbapenem-resistant Citrobacter freundii in a teaching hospital in China. Am J Infect Control. 2011; 39(9):e55-60. DOI: 10.1016/j.ajic.2011.02.009. View

13.

Fournier S, Monteil C, Lepainteur M, Richard C, Brun-Buisson C, Jarlier V . Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Euro Surveill. 2014; 19(19). DOI: 10.2807/1560-7917.es2014.19.19.20802. View

14.

Bleumin D, Cohen M, Moranne O, Esnault V, Benenson S, Paltiel O . Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients. J Infect. 2012; 65(4):318-25. DOI: 10.1016/j.jinf.2012.06.005. View

15.

Ahn J, Song J, Kim M, Choi H, Kim J, Ann H . Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study. Am J Infect Control. 2014; 42(6):621-5. DOI: 10.1016/j.ajic.2014.02.024. View

16.

Lee H, Choi J, Cho S, Kim S, Park S, Choi S . Carbapenem-resistant Enterobacteriaceae: Prevalence and Risk Factors in a Single Community-Based Hospital in Korea. Infect Chemother. 2016; 48(3):166-173. PMC: 5047997. DOI: 10.3947/ic.2016.48.3.166. View

17.

Poulou A, Voulgari E, Vrioni G, Xidopoulos G, Pliagkos A, Chatzipantazi V . Imported Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination. J Clin Microbiol. 2012; 50(8):2618-23. PMC: 3421501. DOI: 10.1128/JCM.00459-12. View

18.

Voor In t Holt A, Severin J, Lesaffre E, Vos M . A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014; 58(5):2626-37. PMC: 3993224. DOI: 10.1128/AAC.01758-13. View

19.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

20.

DerSimonian R, Laird N . Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45(Pt A):139-45. PMC: 4639420. DOI: 10.1016/j.cct.2015.09.002. View